Cargando…

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial

INTRODUCTION: The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin. METHODS: This multicenter, open-label, 26-week phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maniatis, Aristides K., Nadgir, Ulhas, Saenger, Paul, Reifschneider, Kent L., Abuzzahab, Jennifer, Deeb, Larry, Fox, Larry A., Woods, Katie A., Song, Wenjie, Mao, Meng, Chessler, Steven D., Komirenko, Allison S., Shu, Aimee D., Casella, Samuel J., Thornton, Paul S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501775/ https://www.ncbi.nlm.nih.gov/pubmed/35263755 http://dx.doi.org/10.1159/000524003

Ejemplares similares

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency
por: Lin, Zhengning, et al.
Publicado: (2021)

InSiGHT leads in the implementation of the Human Variome Project
por: Macrae, Finlay, et al.
Publicado: (2011)

Somatropin therapy in italian adults with growth hormone deficiency
por: Pricci, Flavia, et al.
Publicado: (2022)

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
por: Frindik, J Paul, et al.
Publicado: (2010)

Iron affects localization of Ght5 in fission yeast
por: Akyüz, Sevim Nur, et al.
Publicado: (2023)

The InSiGHT approach to classification of mismatch repair gene variants
por: Plazzer, JP
Publicado: (2012)

InSiGHT 2022 Abstract Publishing and Best Abstract Awards
Publicado: (2022)

Optimized Signal Peptide for Secretory Expression of Human Recombinant Somatropin in E. coli
por: Ahmadi, Zeynab, et al.
Publicado: (2023)

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients
por: Miller, Bradley S, et al.
Publicado: (2022)

Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database
por: Peltomäki, Päivi, et al.
Publicado: (2004)

Development and Psychometric Evaluation of an Instrument Assessing Barriers to Growth Hormone Treatment (BAR-GHT)
por: de Zwaan, Martina, et al.
Publicado: (2020)

Effect of Twine-arginine Translocation-signaling Fusion System and Chaperones Co-expression on Secretory Expression of Somatropin
por: Bagherinejad, Mohammad Reza, et al.
Publicado: (2018)

Evaluation of human growth hormone (somatropin) in socket healing: a split-mouth randomized controlled trial
por: Sleman, Nadim, et al.
Publicado: (2023)

Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
por: Kuba, Valesca M., et al.
Publicado: (2022)

Adding Ozone to Dextrose and Somatropin for Intra-articular Knee Prolotherapy: A Randomized Single-Blinded Controlled Trial
por: Imani, Farnad, et al.
Publicado: (2020)

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
por: Deal, Cheri L, et al.
Publicado: (2022)

THU164 Design Of The New InsiGHTS Trial: A Multicenter, Phase 2, Randomized, Open-label, Active Controlled Study To Investigate The Safety, Tolerability, And Efficacy Of Lonapegsomatropin In Prepubertal Individuals With Turner Syndrome
por: Klein, Karen O, et al.
Publicado: (2023)

Genetic Analysis and Fine Mapping of ZmGHT1 Conferring Glufosinate Herbicide Tolerance in Maize (Zea mays L.)
por: Bao, Jianxi, et al.
Publicado: (2022)

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014
por: Marcianò, Ilaria, et al.
Publicado: (2018)

Position statement of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) on APC I1307K and cancer risk
por: Valle, Laura, et al.
Publicado: (2023)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020)

Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022)

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
por: Iughetti, Lorenzo, et al.
Publicado: (2016)

Intraocular pressure and diurnal fluctuation of open-angle glaucoma and ocular hypertension: a baseline report from the LiGHT China trial cohort
por: Yang, Yangfan, et al.
Publicado: (2023)

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
por: Gazzard, Gus, et al.
Publicado: (2019)

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
por: Horikawa, Reiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ra7p7cu6600isdd470p76triee